Novo Nordisk to Invest 506 Million in Ireland Plant
Novo Nordisk is investing 506 million dollars to expand its Athlone plant in Ireland. The project aims to boost production of oral versions of its GLP-1 drugs.
Xurve View
Insights:
Xurve View
The pharmaceutical giant Novo Nordisk A/S has announced a significant investment of 432 million euros, approximately $506.43 million, to expand its manufacturing operations in Ireland. The capital will be directed toward the company's existing facility in Athlone, specifically to bolster the production of oral medications.
